Merck & Co., Inc. (FRA:6MK)

Germany flag Germany · Delayed Price · Currency is EUR
74.20
+2.30 (3.20%)
At close: Oct 20, 2025
3.20%
Market Cap188.48B
Revenue (ttm)54.17B
Net Income (ttm)13.97B
Shares Outn/a
EPS (ttm)5.52
PE Ratio13.49
Forward PE9.78
Dividend2.91 (3.92%)
Ex-Dividend DateSep 15, 2025
Volume3,273
Average Volume2,403
Open72.80
Previous Close71.90
Day's Range72.60 - 74.20
52-Week Range65.50 - 102.00
Betan/a
RSI58.26
Earnings DateOct 30, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]

Industry Pharmaceutical Preparations
Founded 1891
Employees 75,000
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6MK
Full Company Profile

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD Financial Statements

News

Trump’s pharma strategy ‘holds Europe hostage’, Finnish MEP warns

Trump’s deals with Pfizer, AstraZeneca, and Merck expose risk to EU

1 day ago - EURACTIV.com

Merck (MRK) Invests $3B in New Pharmaceutical Manufacturing Facility

Merck (MRK) Invests $3B in New Pharmaceutical Manufacturing Facility

1 day ago - GuruFocus

Notable Monday Option Activity: MDGL, MRK, BHVN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Madrigal Pharmaceuticals Inc (Symbol: MDGL), where a total of 1,259 contracts have traded s...

1 day ago - Nasdaq

My Top 3 Pharma Stocks

Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o...

1 day ago - Seeking Alpha

Merck (MRK) Showcases Long-Term Survival Benefits of Keytruda in Lung Cancer Treatment

Merck (MRK) Showcases Long-Term Survival Benefits of Keytruda in Lung Cancer Treatment

1 day ago - GuruFocus

US Supreme Court won't revive mumps vaccine antitrust case against Merck

The U.S. Supreme Court declined on Monday to hear a bid by a group of physicians and healthcare providers to revive their antitrust lawsuit accusing drugmaker Merck of misleading federal regulators to...

1 day ago - Reuters

KEYTRUDA (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 ...

1 day ago - Wallstreet:Online

KEYTRUDA® (pembrolizumab) Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of Non-Small Cell Lung Cancer (NSCLC)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of...

1 day ago - Business Wire

Merck (MRK) Commences $3B Expansion of Virginia Facility

Merck (MRK) Commences $3B Expansion of Virginia Facility

1 day ago - GuruFocus

Merck Starts Construction Of $3 Bln Manufacturing Facility At Its Elkton, Virginia Site

(RTTNews) - Merck & Co., Inc. (MRK), known as MSD outside of the U.S. and Canada, announced Monday the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility...

1 day ago - Nasdaq

Merck begins construction of $3 billion manufacturing facility in Virginia

Merck said on Monday it has begun construction of a $3 billion pharmaceutical manufacturing facility in Elkton, Virginia as part of its more than $70 billion investment to expand domestic manufacturin...

1 day ago - Reuters

Merck breaks ground on $3B manufacturing plant in Virginia

Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion U.S. investment strategy.

1 day ago - Fox Business

Merck's (MRK) Keytruda Shows Promise in Combination with Cylembio for Melanoma

Merck's (MRK) Keytruda Shows Promise in Combination with Cylembio for Melanoma

1 day ago - GuruFocus

Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia.

1 day ago - Business Wire

IO Biotech Reveals Positive Phase 3 Results For Cylembio Plus Keytruda In Advanced Melanoma

(RTTNews) - IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on cancer vaccines, Monday reported positive phase 3 results for Cylembio, in combination with Merck & Co Inc.'s (MRK)...

2 days ago - Nasdaq

Merck (MRK) Reports Promising Keytruda Plus Padcev Results in Bladder Cancer Trial

Merck (MRK) Reports Promising Keytruda Plus Padcev Results in Bladder Cancer Trial

2 days ago - GuruFocus

Merck (MRK) Showcases Promising Long-Term Benefits of Keytruda in Cancer Treatment

Merck (MRK) Showcases Promising Long-Term Benefits of Keytruda in Cancer Treatment

2 days ago - GuruFocus

KEYTRUDA (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluat...

3 days ago - Wallstreet:Online

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE...

3 days ago - Business Wire

Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients

Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of bladder cancer.

3 days ago - Investor's Business Daily

KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) reduced the risk ...

3 days ago - Wallstreet:Online

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating KEYTRUDA® (pembrolizumab) plus Padcev® (enfortuma...

3 days ago - Business Wire

KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced long-term follow-up data continued to show durable benefit of KEYTRUDA (pembrolizumab), Merck’s anti-...

4 days ago - Wallstreet:Online

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial Carcinoma.

4 days ago - Business Wire